First In Human Featured Articles
-
The State Of Clinical Trials In Russia
8/18/2014
Every quarter, Synergy Research Group, a full-service CRO headquartered in Moscow, Russia, issues its Orange Paper. The report, which looks at the state of clinical trials in Russia, is comprised of research done by combing through data from the country’s Ministry of Health. The Orange Paper offers a concise snapshot of clinical trials in the region.
The Q2, 2014 Synergy Orange Paper was just released. One of the more significant findings is that the gap between previous years’ trials and the current period is closing. In the first quarter of 2014, there were 18 percent fewer trials than in the same quarter in 2013. In the second quarter, there was a gap of only three percent.
-
Marijuana And The Pharmaceutical Industry
5/16/2014
An intense shot of pain in my back and side dropped me to the floor. It did not subside. We called 911. A single dose of morphine eased the pain enough so the EMTs could put me on a gurney and into the ambulance for the ride to the emergency room. As I lay in the ambulance my mind wandered.
Morphine is espoused by patients with extreme pain, such as those recovering from major operations like mastectomies. Therefore, anyone over 21 years of age should be able to legally raise poppy plants and/or buy morphine for “recreational” use in their home. We’ll closely monitor any health or other social effects, such as teenage use and car accidents. Sound like a reasonable argument? If not, is there a difference between this thought process and the one of those advocating for legalizing marijuana in the U.S.?